Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808697) titled 'A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants =6 Months to <12 Years of Age' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Prevention. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: ModernaTX, Inc.
Condition:
SARS-CoV-2
Intervention:
Biological: mRNA-1283
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: September 1, 2026
Target Sample Size: 300
Countries of Recruitment:
United States
Arg...